Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quince Therapeutics Inc QNCX

Healthcare Biotechnology
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s... see more

Recent & Breaking News (NDAQ:QNCX)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX

Newsfile February 2, 2022

Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones

Business Wire February 1, 2022

Cortexyme Announces Change in Executive Leadership Team

Business Wire February 1, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

PR Newswire January 27, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Cortexyme, Inc. (CRTX) Investigation

Business Wire January 27, 2022

SHAREHOLDER ALERT: Investigation of Cortexyme, Inc. (CRTX) Announced by Holzer & Holzer, LLC

Newsfile January 26, 2022

Cortexyme Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application

Business Wire January 26, 2022

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

Business Wire November 23, 2021

Cortexyme's Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer's Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

Business Wire November 11, 2021

Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th

Business Wire November 4, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX

PR Newswire November 4, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTX

Newsfile October 29, 2021

Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease Progression

Business Wire October 26, 2021

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease at CTAD 2021

Business Wire September 27, 2021

Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Business Wire September 8, 2021

Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Business Wire September 7, 2021

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer's Disease at Annual Biomarkers for Alzheimer's Disease Summit

Business Wire August 25, 2021

Cortexyme to Present at Annual Biomarkers for Alzheimer's Disease Summit

Business Wire August 18, 2021

Cortexyme Announces Closing of $125 Million Private Placement

Business Wire February 10, 2020

Cortexyme Announces $125 Million Private Placement

Business Wire February 5, 2020